Live feed07:00:00·1476dPRReleasevia QuantisnowSeres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile InfectionByQuantisnow·Wall Street's wire, on your screen.MCRB· Seres Therapeutics Inc.Health Care